Targeting Low-Income Countries With Cost-Effective Rotavirus Vaccines

Rotavirus is a common type of virus that infects the intestine in human body. Easily spread among infants and children, this virus is the most communal cause of diarrhea across the globe, which has caused the death of approximately 500,000 children annually.In few cases even adults become infected of the virus, however the illness is usually mild. 

It is observed that almost 95% of the respective virus happens in young children who belong to low-income countries including Asia and Africa. This can be due to the fact that lifesaving care is limited or not available at all in underdeveloped countries. 

 

In order to prevent oneself, vaccination is the best way that is highly contagious and easily responds to traditional diarrhea prevention methods.Since the year 2006, vaccination for rotavirus infection has been available in the market for public.

The Vaccines

In order to fight against rotavirus, a new vaccine by the name of ROTAVAC® is awaiting licensure in India. If approved, this vaccine could transform the rotavirus children prevention motive including adults cure. The vaccination will be as cheap as $1 per dose to protect children. PATH, a cross-sector partnership led by Indian Government was involved in the development of vaccine. It provided technical support on various basic as well as critical clinical trials and manufacturing issues. PATH is also in close coordination with the manufacturers in China, India, and the United States to safeguard other rotavirus vaccine candidates, out of whom some are under clinical trials.

Apart from this, there are two existing rotavirus vaccines available across the geographies and are highly safe to use. These vaccinations are so effective that countries have seen drastic reductions in severe and fatal diarrhea. 

The Future

After receiving license for ROTAVAC in India, the owners can submit the vaccine to World Health Organization for prequalification. This will be a significant step in targeting effected children all over the countries with the pocket-friendly vaccine.

3 Things you must know about Vaccine Research and Development

Vaccine research and development, initiates the purpose of combating deadliest of diseases as per the standards and guidelines adhering to both developed and developing nations. The Vaccine research is based on regional epidemic of a nation.  The Development of the vaccine is initiated with sole purpose of producing an anti-dote for a particular disease. The Research and Development process of vaccine development includes three important factors:

• Identifying Vaccine Research Priorities

Since the research on vaccine has found adequate supports, the demand for independent evaluation has increased considerably. There, now, has to be stringent assessment of priorities, effort coordination for activities optimization and alignment. Hilleman Labs, a vaccine development company, has been helping developing countries fight deadliest of the diseases by offering affordable vaccinations. It has also identified relevant gaps and stimulated the implementation of technical agendas.

• Developing Research standards and guiding principles

Guidelines are necessary for new vaccine candidates, as their course of action is complex and they use multiple clinical demonstrations to target diseases. Certain standards have been defined by WHO such as Quality, Safety and Standards Unit, Harmonized Methods, and tools for comparing research results.

• Research and Product Development Capacity Growth

Many countries have shown interest in developing and producing quality vaccines. The developing nations can utilize the Research and Development capacity of World Health Organization, as its integral project development. The WHO offers clinical guidance support and practice for development of research centers and technology hubs.

Examine the Rise and Fall of Immunization Cost in Developing Countries and its Usefulness

For the developing countries, vaccines have made feasible some of the greatest public health successes in the last decade. The supply of high-impact Immunization helps avert an estimated 2.5 million child deaths each year. Vaccinesmanufacturing laboratories are striving to spread awareness about the up and coming technologies & processes executed in the field of vaccine development. The process of vaccine development involves high investment costs and the facilities require the optimum use of resources. Apart from the cost, there is no dearth of speculations involved when it comes to acquiring high quality and effective vaccinations for the general public. It also requires adequate research and development, quality control and quality assurance in the field of vaccination. However, the investment cost has been an important aspect to maintain world-class infrastructure for vaccine. As resources and facilities for vaccines manufacturing are available in abundance, on the other hand laboratories have to face a number of problems to initiate a research and development in developing countries. In addition, the world’s vaccine market is very small—below 2 percent of the pharmaceutical market—attracting few suppliers.

It has been examined that the prices of traditional vaccines have decreased significantly. The immunization cost of traditional six vaccines of the Expanded Programme on Immunization (EPI), measles, diphtheria, pertussis, tetanus, oral polio and BCG has shown a radical decrease in cost. Because the fixed costs of development of these vaccines have been covered long ago, and because their production costs have been lowered due to the learning curve and economies of scale, their prices are relatively low.  In the past years, there has been excess production capacity of these vaccines as new producers have entered the market, thus sales at low prices covered the variable costs of producing extra doses of vaccine, and did not require additional capacity.

Hilleman Laboratories is intended to participate actively to develop and optimize vaccines for developing countries to ensure healthy tomorrow while keeping its investment costs in control. The lab understands the constant need of vaccines by developing countries and for this reason puts more emphasis on the supply of high impact immunization for kids and even promotes awareness campaigns in rural areas about how to keep track on immunizationschedule for kids. The lab develops high-impact, thermal stable and cost-effective pneumococcal vaccine and conjugate vaccine for developing countries. Hilleman Laboratories was set up in 2009, the first time a research charity joined hands with a drug maker to develop affordable vaccines to prevent diseases that commonly affect people in low-income countries. The firm has successfully promoted and supplied a heat stable, affordable and easy-to-use rotavirus vaccines used to prevent diarrhoea in children.






Corporate Office and R&D Laboratory

MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.
2nd Floor, Nanotechnology Building, Jamia Hamdard

Hamdard Nagar, New Delhi – 110062 (India)

Ph: +91 11 30997700 Fax: +91 11 30997711

Website: www.hillemanlabs.org

Ensuring Global Health through Vaccine Optimization for a Better Tomorrow

Development of vaccine is a strategic, slow and complex process that can be initiated by reliable and experienced labs. Over a time the system for developing, testing and regulating vaccine optimization has been modified to ensure improved performance. These days testing labs are adopting updated standards and regulatory policies to develop safe vaccines of high quality which are giving good results. The involvements of certain steps in vaccine delivery are significant to reduce the risks and improve the overall results. The process which has been followed to develop vaccines are being tested, and regulated in a very similar manner to other drugs. In general, vaccines are even more thoroughly tested than non-vaccine drugs because the number of human subjects in vaccine clinical trials is usually greater. In addition, post-development monitoring of vaccines is closely examined by the higher departments of disease control.

Safety is also an important phase in different types of the vaccine development process utilized by numerous labs all across the globe. Proven adverse events from the use of licensed vaccines are rare, and vaccines with known safety problems have been removed from the market. Successful vaccinations are highly effective and used globally in order to ensure critical health aspects with the removal of long medication processes. We have been heard that precautions is better than cure, vaccine is supporting this fact on the whole.

Immunization chart is the best and only way that parents can adopt to reduce the chances of skipping any of the vaccine of their child in the initial years of the birth. This chart includes age, vaccination name and how it is given, that facilitates you to track and not to skip any vaccination of your child and brought consistency.

Apart all the benefits of developing a vaccine, it has some major or minor obstacles that can be broadly classified as economic obstacles, technical obstacles and cultural obstacles. Successful vaccines have the scope of introducing and supporting new programs to deliberately providing positive consequences. Vaccines have helped eradicate the worst infectious diseases in the developed world. Research and development must continue the progress of the past and address those diseases that have eluded the development of effective vaccines and the diseases that continue to devastate regions where vaccines have been unavailable. Research is also needed to improve existing vaccines.

There are certain misconceptions related to vaccination, that it should fulfill a net cost-savings is a major obstacle to vaccine development. As a matter of fact costing of vaccination is one of major obstacle in India or outside. To resolve this with consistent approach governments and individuals should be prepared to pay a certain cost to improve health and avoid suffering. Recently studies shows that vaccine development is hampered by the current pricing structure in the U.S., which for some diseases fails to allow adequate compensation for the companies that develop vaccines in the early years following license. Paying prices for vaccines that take into account their health and lifesaving attributes, would encourage more research, more innovation, and better, safer vaccines.